Prexige to be withdrawn in Canada
2007-10-22
October 4, 2007, Health Canada the equivalent of the Saudi Food and Drug Authority (SFDA), announced that it has stopped the sale of the anti-inflammatory drug Prexige (lumiracoxib) in Canada and will cancel the drug's market authorization due to the potential for serious liver-related adverse events
Prexige, a Cox-2 selective inhibitor non-steroidal anti-inflammatory drug, and used for the treatment of the signs and symptoms of osteoarthritis in adults at a maximum daily dose of 100 milligrams (mg).